Drug
Argx 113
Argx 113: highest development phase Phase 1, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-113 NCT03457649 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Argx 113 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.